Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)
 
 • Company Description   
Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

Number of Employees: 188

 
 • Price / Volume Information   
Yesterday's Closing Price: $89.68 Daily Weekly Monthly
20 Day Moving Average: 1,277,789 shares
Shares Outstanding: 71.95 (millions)
Market Capitalization: $6,452.39 (millions)
Beta: 2.28
52 Week High: $103.00
52 Week Low: $19.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 40.94% 39.08%
12 Week 75.29% 70.28%
Year To Date 122.92% 86.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 North Beacon Street 4th Floor
-
Watertown,MA 02472
USA		 ph: 857-285-5300
fax: -		 investors@kymeratx.com http://www.kymeratx.com
 
 • General Corporate Information   
Officers
Nello Mainolfi - Chief Executive Officer and President
Bruce Booth - Chair of the Board of Directors
Bruce Jacobs - Chief Financial Officer
Felix Baker - Director
Jeff Albers - Director

Peer Information
Kymera Therapeutics, Inc. (CORR.)
Kymera Therapeutics, Inc. (RSPI)
Kymera Therapeutics, Inc. (CGXP)
Kymera Therapeutics, Inc. (BGEN)
Kymera Therapeutics, Inc. (GTBP)
Kymera Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501575104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
Share - Related Items
Shares Outstanding: 71.95
Most Recent Split Date: (:1)
Beta: 2.28
Market Capitalization: $6,452.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/26/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.78
Price/Cash Flow: -
Price / Sales: 147.54
EPS Growth
vs. Year Ago Period: -9.76%
vs. Previous Quarter: 5.26%
Sales Growth
vs. Year Ago Period: -26.12%
vs. Previous Quarter: -75.91%
ROE
09/30/25 - -32.92
06/30/25 - -31.60
03/31/25 - -30.11
ROA
09/30/25 - -28.21
06/30/25 - -27.12
03/31/25 - -25.65
Current Ratio
09/30/25 - 7.38
06/30/25 - 8.32
03/31/25 - 8.49
Quick Ratio
09/30/25 - 7.38
06/30/25 - 8.32
03/31/25 - 8.49
Operating Margin
09/30/25 - -666.00
06/30/25 - -616.03
03/31/25 - -409.07
Net Margin
09/30/25 - -674.81
06/30/25 - -616.03
03/31/25 - -409.07
Pre-Tax Margin
09/30/25 - -674.81
06/30/25 - -616.03
03/31/25 - -409.07
Book Value
09/30/25 - 13.23
06/30/25 - 14.92
03/31/25 - 12.07
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 0.19
06/30/25 - 0.23
03/31/25 - 0.24
 

Powered by Zacks Investment Research ©